⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.
Rotigotine
روتیگوتین
🧠 Nervous SystemDopamine agonist (patch)
🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Safety not established👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA021829ATC N04BC09
Market / country: 🇺🇸 USA
Neupro (US)
🧮 Dose calculator
Parkinson's disease · Regimen source: FDA Neupro · 2.1
- • One patch daily on intact skin (abdomen, thigh, hip, flank, shoulder, upper arm); rotate the site daily. Taper: max 2 mg every other day. FDA Neupro · 2.3FDA Neupro · 2.4
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to rotigotine or the patch components. FDA Neupro · 4
Warnings
- • Falling asleep during daily activities; hallucinations; hypotension and syncope; impulse-control/compulsive behaviours (gambling, shopping); dyskinesia; hyperpyrexia and confusion on abrupt withdrawal. FDA Neupro · 5
- • Sulfite sensitivity; increased blood pressure and heart rate; augmentation in RLS; remove before MRI or cardioversion (burns); no heat over the patch. FDA Neupro · 5
Formulations
- 2 mg/24 h patch — transdermal patch 🇺🇸 USA FDA Neupro · 3
- 4 mg/24 h patch — transdermal patch 🇺🇸 USA FDA Neupro · 3
- 6 mg/24 h patch — transdermal patch 🇺🇸 USA FDA Neupro · 3
- 8 mg/24 h patch — transdermal patch 🇺🇸 USA FDA Neupro · 3
- 1 mg/24 h patch — transdermal patch 🇺🇸 USA FDA Neupro · 3
- 3 mg/24 h patch — transdermal patch 🇺🇸 USA FDA Neupro · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Neupro · 8.1
“Risk Summary There are no adequate data on the developmental risk associated with the use of NEUPRO in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Neupro · 8.2
“Risk Summary There are no data on the presence of rotigotine in human milk, the effects of rotigotine on the breastfed infant, or the effects of rotigotine on milk production.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Neupro · 8.4
“Safety and effectiveness in pediatric patients for any indication have not been established.”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Neupro · 8.5
“No overall differences in plasma levels of rotigotine were observed between patients who were 65 to 80 years old compared with younger patients receiving the same rotigotine doses.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA021829
- DailyMed (FDA label)FDA Neupro
- MedlinePlus (NIH)Rotigotine Transdermal Patch
- WHO ATC/DDDN04BC09
- Darooyab (Iran)Rotigotine
🇮🇷 Registered in Iran Darooyab · G-5520/Rotigotine
Dosage forms with Iranian generic codes, per Darooyab.
- 50757 · ROTIGOTINE PATCH TRANSDERMAL 13.5 mg/30cm2 · پچ پوستی روتیگوتین ۱۳٫۵ میلیگرم / ۳۰ سانتیمتر ۲
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Neupro · 3FDA Neupro · 2.1FDA Neupro · 2.3FDA Neupro · 2.4FDA Neupro · 2.2FDA Neupro · 4FDA Neupro · 5FDA Neupro · SPL approval / marketing categoryFDA Neupro · 8.1FDA Neupro · 8.2FDA Neupro · 8.4FDA Neupro · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-5520/Rotigotine
- Clinical review⚠ Unverified